鱼跃医疗五代CGM实现AI融合，准确率提升，产品使用周期延至行业最长

Core Insights - Yuyue Medical's 2024 annual report reveals that the blood glucose segment's revenue has surpassed 1 billion yuan for the first time, with a year-on-year growth exceeding 40% [1] - The company attributes this rapid growth to innovation in research and development, production optimization, and high customer satisfaction, which have strengthened its market position [1] - The Continuous Glucose Monitoring (CGM) products have seen a doubling in growth, marking the beginning of a second growth curve in blood glucose management for the company [1] Revenue and Market Performance - The blood glucose segment's revenue reached over 1 billion yuan, reflecting a growth rate of more than 40% year-on-year [1] - The CGM products have achieved significant performance improvements, with the latest generation sensors having a usage cycle of 16 days, the longest in the industry [1][2] - The MARD value of the new CGM products is reported at 8.58%, indicating high accuracy and stability, which has been recognized by clinical experts [2] Product Development and Innovation - The company has launched the Anytime 5 series CGM products, which have already achieved over 50,000 units sold online within a month of release, demonstrating strong market demand [3] - The CGM technology is positioned as a leading-edge solution for diabetes management, offering continuous monitoring without the need for frequent blood sampling [2] - The integration of AI with CGM data aims to provide personalized blood glucose management solutions, enhancing the transition of healthcare from hospitals to home settings [3] Market Trends and Future Outlook - The global CGM market is projected to reach $36.4 billion by 2030, with China's market expected to reach 5 billion yuan, driven by an aging population and increasing diabetes prevalence [2] - The CGM products are still in the early stages of market penetration in China, indicating significant growth potential as domestic companies achieve technological breakthroughs [2] - The combination of AI and CGM technology is expected to reshape diabetes prevention and management, moving from reactive treatment to proactive prevention [3]